Compare Tsumura & Co. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 12.53% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate 12.53% of over the last 5 years
3
The company has declared Negative results for the last 5 consecutive quarters
4
With ROE of 10.08%, it has a very attractive valuation with a 0.95 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 296,364 Million (Small Cap)
9.00
NA
0.00%
0.16
9.58%
0.92
Revenue and Profits:
Net Sales:
49,704 Million
(Quarterly Results - Jun 2026)
Net Profit:
6,723 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.94%
0%
3.94%
6 Months
-10.13%
0%
-10.13%
1 Year
4.58%
0%
4.58%
2 Years
-0.24%
0%
-0.24%
3 Years
45.01%
0%
45.01%
4 Years
20.67%
0%
20.67%
5 Years
6.53%
0%
6.53%
Tsumura & Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.24%
EBIT Growth (5y)
12.53%
EBIT to Interest (avg)
70.70
Debt to EBITDA (avg)
0.22
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.45
Tax Ratio
26.30%
Dividend Payout Ratio
39.07%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
9.83%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.95
EV to EBIT
9.69
EV to EBITDA
7.27
EV to Capital Employed
0.96
EV to Sales
1.87
PEG Ratio
1.16
Dividend Yield
NA
ROCE (Latest)
9.86%
ROE (Latest)
10.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2020
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
49,704.00
43,094.00
15.34%
Operating Profit (PBDIT) excl Other Income
11,580.00
10,684.00
8.39%
Interest
547.00
147.00
272.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6,723.00
4,441.00
51.38%
Operating Profit Margin (Excl OI)
158.60%
179.10%
-2.05%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 15.34% vs -1.36% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 51.38% vs -61.03% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
192,615.00
181,093.00
6.36%
Operating Profit (PBDIT) excl Other Income
48,282.00
51,296.00
-5.88%
Interest
2,152.00
518.00
315.44%
Exceptional Items
-776.00
-32.00
-2,325.00%
Consolidate Net Profit
30,242.00
34,523.00
-12.40%
Operating Profit Margin (Excl OI)
182.90%
221.60%
-3.87%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 6.36% vs 20.05% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -12.40% vs 91.31% in Mar 2025
About Tsumura & Co. 
Tsumura & Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






